252 related articles for article (PubMed ID: 32848031)
1. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants.
Dekkers G; Brouwer MC; Jeremiasse J; Kamp A; Biggs RM; van Mierlo G; Lauder S; Katti S; Kuijpers TW; Rispens T; Jongerius I
J Immunol; 2020 Oct; 205(7):1778-1786. PubMed ID: 32848031
[TBL] [Abstract][Full Text] [Related]
2. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.
Hyvärinen S; Meri S; Jokiranta TS
Blood; 2016 Jun; 127(22):2701-10. PubMed ID: 27006390
[TBL] [Abstract][Full Text] [Related]
3. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
Pechtl IC; Kavanagh D; McIntosh N; Harris CL; Barlow PN
J Biol Chem; 2011 Apr; 286(13):11082-90. PubMed ID: 21270465
[TBL] [Abstract][Full Text] [Related]
4. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.
Józsi M; Strobel S; Dahse HM; Liu WS; Hoyer PF; Oppermann M; Skerka C; Zipfel PF
Blood; 2007 Sep; 110(5):1516-8. PubMed ID: 17495132
[TBL] [Abstract][Full Text] [Related]
5. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
Ueda Y; Miwa T; Ito D; Kim H; Sato S; Gullipalli D; Zhou L; Golla M; Song D; Dunaief JL; Palmer MB; Song WC
Kidney Int; 2019 Jul; 96(1):67-79. PubMed ID: 30910380
[TBL] [Abstract][Full Text] [Related]
6. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.
Ferreira VP; Herbert AP; Cortés C; McKee KA; Blaum BS; Esswein ST; Uhrín D; Barlow PN; Pangburn MK; Kavanagh D
J Immunol; 2009 Jun; 182(11):7009-18. PubMed ID: 19454698
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera.
Pouw RB; Brouwer MC; de Gast M; van Beek AE; van den Heuvel LP; Schmidt CQ; van der Ende A; Sánchez-Corral P; Kuijpers TW; Wouters D
Blood Adv; 2019 Feb; 3(4):621-632. PubMed ID: 30804016
[TBL] [Abstract][Full Text] [Related]
8. Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces.
Dopler A; Stibitzky S; Hevey R; Mannes M; Guariento M; Höchsmann B; Schrezenmeier H; Ricklin D; Schmidt CQ
Front Immunol; 2021; 12():615748. PubMed ID: 33732239
[TBL] [Abstract][Full Text] [Related]
9. Complement Genetic Variants and FH Desialylation in
Gómez Delgado I; Corvillo F; Nozal P; Arjona E; Madrid Á; Melgosa M; Bravo J; Szilágyi Á; Csuka D; Veszeli N; Prohászka Z; Sánchez-Corral P
Front Immunol; 2021; 12():641656. PubMed ID: 33777036
[TBL] [Abstract][Full Text] [Related]
10. High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele
Pouw RB; Gómez Delgado I; López Lera A; Rodríguez de Córdoba S; Wouters D; Kuijpers TW; Sánchez-Corral P
Front Immunol; 2018; 9():848. PubMed ID: 29740447
[TBL] [Abstract][Full Text] [Related]
11. Complete functional characterization of disease-associated genetic variants in the complement factor H gene.
Merinero HM; García SP; García-Fernández J; Arjona E; Tortajada A; Rodríguez de Córdoba S
Kidney Int; 2018 Feb; 93(2):470-481. PubMed ID: 28941939
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome.
Sánchez-Corral P; Pérez-Caballero D; Huarte O; Simckes AM; Goicoechea E; López-Trascasa M; de Córdoba SR
Am J Hum Genet; 2002 Dec; 71(6):1285-95. PubMed ID: 12424708
[TBL] [Abstract][Full Text] [Related]
13. Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.
Ueda Y; Miwa T; Gullipalli D; Sato S; Ito D; Kim H; Palmer M; Song WC
J Am Soc Nephrol; 2018 Jul; 29(7):1928-1937. PubMed ID: 29858280
[No Abstract] [Full Text] [Related]
14. Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients.
Mohlin FC; Nilsson SC; Levart TK; Golubovic E; Rusai K; Müller-Sacherer T; Arbeiter K; Pállinger É; Szarvas N; Csuka D; Szilágyi Á; Villoutreix BO; Prohászka Z; Blom AM
Mol Immunol; 2015 Jun; 65(2):367-76. PubMed ID: 25733390
[TBL] [Abstract][Full Text] [Related]
15. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.
Lehtinen MJ; Rops AL; Isenman DE; van der Vlag J; Jokiranta TS
J Biol Chem; 2009 Jun; 284(23):15650-8. PubMed ID: 19351878
[TBL] [Abstract][Full Text] [Related]
16. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
Blanc C; Togarsimalemath SK; Chauvet S; Le Quintrec M; Moulin B; Buchler M; Jokiranta TS; Roumenina LT; Fremeaux-Bacchi V; Dragon-Durey MA
J Immunol; 2015 Jun; 194(11):5129-38. PubMed ID: 25917093
[TBL] [Abstract][Full Text] [Related]
17. Mutations in Complement Factor H Impair Alternative Pathway Regulation on Mouse Glomerular Endothelial Cells in Vitro.
Loeven MA; Rops AL; Lehtinen MJ; van Kuppevelt TH; Daha MR; Smith RJ; Bakker M; Berden JH; Rabelink TJ; Jokiranta TS; van der Vlag J
J Biol Chem; 2016 Mar; 291(10):4974-81. PubMed ID: 26728463
[TBL] [Abstract][Full Text] [Related]
18. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.
Valoti E; Alberti M; Iatropoulos P; Piras R; Mele C; Breno M; Cremaschi A; Bresin E; Donadelli R; Alizzi S; Amoroso A; Benigni A; Remuzzi G; Noris M
Front Immunol; 2019; 10():853. PubMed ID: 31118930
[TBL] [Abstract][Full Text] [Related]
19. Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases.
Recalde S; Tortajada A; Subias M; Anter J; Blasco M; Maranta R; Coco R; Pinto S; Noris M; García-Layana A; Rodríguez de Córdoba S
J Am Soc Nephrol; 2016 May; 27(5):1305-11. PubMed ID: 26376859
[TBL] [Abstract][Full Text] [Related]
20. Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies.
Loeven MA; Maciej-Hulme ML; Yanginlar C; Hubers MC; Kellenbach E; de Graaf M; van Kuppevelt TH; Wetzels J; Rabelink TJ; Smith RJH; van der Vlag J
Front Immunol; 2021; 12():676662. PubMed ID: 34489931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
